New hope for Hard-to-Treat cancers: GAIA-102 trial targets malignant ascites
NCT ID NCT05438459
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial is testing a new biological therapy called GAIA-102, alone or combined with the immunotherapy pembrolizumab, for people with advanced stomach or pancreatic cancer that has spread and caused fluid buildup in the abdomen (malignant ascites). The study has two parts: first, to find a safe dose, and second, to see if the treatment helps people live longer compared to standard therapy. About 130 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GAIA-102 (a biological therapy) and pembrolizumab (an immunotherapy)
- What this could lead to
- If successful, this could offer a new treatment option for advanced gastrointestinal cancers with malignant ascites, potentially extending survival and controlling disease.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply broadly. There are risks of side effects from the therapies, and the combination may not prove more effective than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kyushu University Hospital
RECRUITINGFukuoka, Fukuoka, 812-8582, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication